DE69329643D1 - Gegen karzinom-assoziierte antigene gerichtete antikörper - Google Patents
Gegen karzinom-assoziierte antigene gerichtete antikörperInfo
- Publication number
- DE69329643D1 DE69329643D1 DE69329643T DE69329643T DE69329643D1 DE 69329643 D1 DE69329643 D1 DE 69329643D1 DE 69329643 T DE69329643 T DE 69329643T DE 69329643 T DE69329643 T DE 69329643T DE 69329643 D1 DE69329643 D1 DE 69329643D1
- Authority
- DE
- Germany
- Prior art keywords
- antique
- antibodies
- against carcinoma
- carcinoma
- associated antique
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000009030 Carcinoma Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86835292A | 1992-04-13 | 1992-04-13 | |
PCT/US1993/001960 WO1993020841A1 (en) | 1992-04-13 | 1993-03-05 | Antibodies specific for carcinoma-associated antigens |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69329643D1 true DE69329643D1 (de) | 2000-12-14 |
DE69329643T2 DE69329643T2 (de) | 2001-03-01 |
Family
ID=25351500
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69329643T Expired - Lifetime DE69329643T2 (de) | 1992-04-13 | 1993-03-05 | Gegen karzinom-assoziierte antigene gerichtete antikörper |
Country Status (7)
Country | Link |
---|---|
US (1) | US5506343A (de) |
EP (1) | EP0636029B1 (de) |
JP (1) | JP3698370B2 (de) |
AU (1) | AU683413B2 (de) |
CA (1) | CA2118010C (de) |
DE (1) | DE69329643T2 (de) |
WO (1) | WO1993020841A1 (de) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6222020B1 (en) * | 1987-01-07 | 2001-04-24 | Imperial Cancer Research Technology Limited | Antigens derived from the core protein of the human mammary epithelial mucin |
US6548643B1 (en) | 1994-11-16 | 2003-04-15 | Austin Research Institute | Antigen carbohydrate compounds and their use in immunotherapy |
US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
US6896849B2 (en) * | 1998-10-29 | 2005-05-24 | Applera Corporation | Manually-operable multi-well microfiltration apparatus and method |
US6906292B2 (en) * | 1998-10-29 | 2005-06-14 | Applera Corporation | Sample tray heater module |
US6716966B1 (en) | 1999-08-18 | 2004-04-06 | Altarex Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
US7147850B2 (en) * | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
WO2001012217A1 (en) * | 1999-08-18 | 2001-02-22 | Altarex Corp. | Therapeutic antibody against muc-1 antigen and methods for their use |
US20040018181A1 (en) * | 2000-09-11 | 2004-01-29 | KUFE Donald W. | MUC1 interference RNA compositions and methods derived therefrom |
KR20030068536A (ko) * | 2000-09-11 | 2003-08-21 | 다나-파버 캔서 인스티튜트 | Muc1 세포외 도메인 및 이로부터 유래된 암 치료조성물과 방법 |
WO2002058450A2 (en) | 2000-12-22 | 2002-08-01 | Dana-Faber Cancer Institute, Inc. | Regulation of cell growth by muc1 |
EP1383802A4 (de) * | 2001-03-30 | 2005-08-03 | Univ California | Anti-muc-1-einzelkettenantikörper zum targeting von tumoren |
US7183388B2 (en) * | 2001-03-30 | 2007-02-27 | The Regents Of The University Of California | Anti-MUC-1 single chain antibodies for tumor targeting |
US7074175B2 (en) | 2001-07-25 | 2006-07-11 | Erik Schroeder Handy | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US7731648B2 (en) * | 2001-07-25 | 2010-06-08 | Aduro Biotech | Magnetic nanoscale particle compositions, and therapeutic methods related thereto |
US6997863B2 (en) * | 2001-07-25 | 2006-02-14 | Triton Biosystems, Inc. | Thermotherapy via targeted delivery of nanoscale magnetic particles |
US7951061B2 (en) * | 2001-07-25 | 2011-05-31 | Allan Foreman | Devices for targeted delivery of thermotherapy, and methods related thereto |
US7247297B2 (en) * | 2001-09-14 | 2007-07-24 | The University Of Chicago | Use of DF3/MUC1 regulated expression in gene therapy |
CA2481796A1 (en) * | 2002-04-11 | 2003-10-23 | Altarex Medical Corporation | Binding agents and their use in targeting tumor cells |
DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
US20040156846A1 (en) * | 2003-02-06 | 2004-08-12 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles using L6 antibodies |
WO2004092339A2 (en) * | 2003-04-11 | 2004-10-28 | Ilex Products, Inc. | Modulation of muc1 mediated signal transduction |
US8129506B2 (en) | 2003-10-24 | 2012-03-06 | Genzyme Corporation | Modulation of the interaction of MUC1 with MUC1 ligands |
JP2007523214A (ja) * | 2004-02-23 | 2007-08-16 | ジェンザイム コーポレイション | デスレセプターリガンド誘導アポトーシスのmuc1アンタゴニスト増強方法 |
JP2008534970A (ja) * | 2005-04-04 | 2008-08-28 | ヴィヴェンティア バイオテック インコーポレーティッド | 抗原の同定のための方法および系 |
CA2623517A1 (en) | 2005-09-23 | 2007-04-05 | Walter Reed Army Institute Of Research (Wrair) | Antibodies with simultaneous subsite specificities to protein and lipid epitopes |
WO2008111996A2 (en) * | 2006-07-20 | 2008-09-18 | Dana-Farber Cancer Institute, Inc. | Muc1-ikb kinase complexes and their activities |
WO2008028686A2 (en) | 2006-09-10 | 2008-03-13 | Glycotope Gmbh | Use of human cells of myeloid leukaemia origin for expression of antibodies |
EP1920781B1 (de) | 2006-11-10 | 2015-03-04 | Glycotope GmbH | Zusammensetzungen die ein Core-1 positives Mikroorganismus enthalten und deren Verwendung zur Behandlung von Tumoren |
US7972870B2 (en) | 2007-02-02 | 2011-07-05 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3 |
WO2008097844A2 (en) | 2007-02-02 | 2008-08-14 | Dana -Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins |
CN102264765B (zh) | 2008-10-28 | 2016-01-20 | 盐野义制药株式会社 | 抗muc1抗体 |
EP2281844A1 (de) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | MUC-1-Antikörper |
WO2011054359A2 (en) | 2009-11-06 | 2011-05-12 | University Of Copenhagen | Method for early detection of cancer |
WO2011135869A1 (ja) | 2010-04-28 | 2011-11-03 | 塩野義製薬株式会社 | 新規なmuc1抗体 |
EP2748302B1 (de) | 2011-08-22 | 2018-08-15 | Glycotope GmbH | Mikroorganismen mit einem tumor-antigen |
AU2015254257B2 (en) | 2014-04-28 | 2021-02-25 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof |
WO2019077951A1 (ja) * | 2017-10-16 | 2019-04-25 | 学校法人東京医科大学 | Muc1に対する抗体またはその抗原結合断片、それらのコード遺伝子、およびその用途 |
WO2019219889A1 (en) | 2018-05-18 | 2019-11-21 | Glycotope Gmbh | Anti-muc1 antibody |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0108146B1 (de) * | 1982-05-12 | 1987-01-28 | The President And Fellows Of Harvard College | Hybridproteinekodierende fusionierte Gene, sie enthaltende Klonierungsvektoren und deren Verwendung |
ATE92081T1 (de) * | 1986-04-17 | 1993-08-15 | Hybritech Inc | Tumorassoziiertes antigen. |
US4894227A (en) * | 1986-08-01 | 1990-01-16 | Cetus Corporation | Composition of immunotoxins with interleukin-2 |
US4963484A (en) * | 1988-01-29 | 1990-10-16 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
US5053489A (en) * | 1988-01-29 | 1991-10-01 | Dana-Farber Cancer Institute, Inc. | Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen |
WO1990005142A1 (en) * | 1988-11-10 | 1990-05-17 | Imperial Cancer Research Technology Ltd. | Polypeptides |
CA2003211A1 (en) * | 1988-11-17 | 1990-05-17 | Pei-Xiang Xing | Monoclonal antibodies |
DE4133791A1 (de) * | 1991-10-11 | 1993-04-15 | Behringwerke Ag | Monoklonale antikoerper gegen tumorassoziierte antigene, verfahren zu ihrer herstellung und ihre verwendung |
CA2082605C (en) * | 1991-12-30 | 2005-02-01 | James J. Elting | Monitoring of nca-bt in blood samples of breast cancer patients |
-
1993
- 1993-03-05 CA CA002118010A patent/CA2118010C/en not_active Expired - Lifetime
- 1993-03-05 DE DE69329643T patent/DE69329643T2/de not_active Expired - Lifetime
- 1993-03-05 EP EP93907209A patent/EP0636029B1/de not_active Expired - Lifetime
- 1993-03-05 JP JP51830893A patent/JP3698370B2/ja not_active Expired - Fee Related
- 1993-03-05 WO PCT/US1993/001960 patent/WO1993020841A1/en active IP Right Grant
- 1993-03-05 AU AU37894/93A patent/AU683413B2/en not_active Ceased
-
1994
- 1994-10-25 US US08/328,536 patent/US5506343A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2118010A1 (en) | 1993-10-28 |
EP0636029A4 (de) | 1996-10-09 |
EP0636029A1 (de) | 1995-02-01 |
JP3698370B2 (ja) | 2005-09-21 |
US5506343A (en) | 1996-04-09 |
AU3789493A (en) | 1993-11-18 |
JPH07505775A (ja) | 1995-06-29 |
WO1993020841A1 (en) | 1993-10-28 |
EP0636029B1 (de) | 2000-11-08 |
CA2118010C (en) | 2003-10-28 |
DE69329643T2 (de) | 2001-03-01 |
AU683413B2 (en) | 1997-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69329643D1 (de) | Gegen karzinom-assoziierte antigene gerichtete antikörper | |
DK145493D0 (da) | Antistof | |
DK0574782T3 (da) | Dobbeltanalyt-immunassay | |
DE59207340D1 (de) | Spulenaufbau | |
NO931887L (no) | Ladeutstyr | |
ITMI911140A0 (it) | Iniettore gascromatografico | |
DE69328960D1 (de) | Kopiergerät | |
FI98746C (fi) | Päällystyslaite | |
NO304503B1 (no) | Hydrosyklon | |
NO920523L (no) | Ige-reseptor-antistoff | |
DE69319724T2 (de) | Spulenstruktur | |
DE59307896D1 (de) | Kopiervorrichtung | |
TR25655A (tr) | Gizli | |
KR910015317U (ko) | 바인다 | |
FIU920746U0 (fi) | Eldstad | |
FIU920104U0 (fi) | Eldstad | |
BR9202706A (pt) | Fogareiro portatil desmontavel | |
ITPD910069U1 (it) | Struttura di bobina | |
SE9202513D0 (sv) | Reflexanordning | |
TR24488A (tr) | Gizli | |
TR24190A (tr) | Gizli | |
TR24192A (tr) | Gizli | |
TR24194A (tr) | Gizli | |
TR24314A (tr) | Gizli | |
TR24191A (tr) | Gizli |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |